TG Therapeutics Q2 net loss $78.5M; UKONIQ revenue $1.5M; U2 PDUFA March 2022

TG THERAPEUTICS, INC.

2022-Q2 EPS reported -$1.28 revenue$2,338,000

Net loss $78.5M for Q2 2021, up from $52.9M in Q2 2020; ex-stock comp net loss ~$62.2M.
UKONIQ net revenue $1.5M in Q2 (total $2.3M since Feb 2021 launch); product revenue zero year ago.
FDA accepted BLA/sNDA for U2 (ublituximab+UKONIQ) in CLL/SLL; PDUFA goal date March 25, 2022.
Cash $456.2M at June 30, 2021; company expects to fund operations into 2023.
Plan to submit BLA for ublituximab in relapsing MS in Q3 2021 based on positive Phase 3 results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.